Successful allogeneic bone marrow transplant for Niemann-Pick disease type C2 is likely to be associated with a severe 'graft versus substrate' effect.
Niemann-Pick disease type C2 (NPC2) is caused by the inherited deficiency of a lysosomal cholesterol transport protein, NPC2 protein. Many cases of NPC2 present in early infancy with inflammatory lung disease, with subsequent severe neurological disease and death in early childhood. This disease is theoretically correctable by bone marrow transplantation (BMT), as the NPC2 protein is small and soluble and secreted and recaptured by the mannose-6-phosphate pathway. In this report we describe the first successful allogeneic bone marrow transplantation for this condition in a 16-month-old boy homozygous for the NPC2 p.E20X mutation, which has hitherto been reported to cause disease with a severe phenotype. During BMT there was an initial improvement of the established respiratory illness, with the immune suppression associated with transplant conditioning, but there was subsequent marked deterioration at the time of immune reconstitution and donor cell engraftment. This 'graft versus substrate' reaction was managed with intensive immune suppressant therapy, and it gradually resolved as the substrate was cleared by the engrafted donor macrophages. All immune suppression was withdrawn 18 months after transplantation, and his respiratory illness has resolved. He walked independently at 24 months and is continuing to reach development milestones after receiving his transplant. We conclude that the successful treatment of Niemann-Pick C2 therefore seems likely to be associated with a severe post-transplantation 'graft versus substrate' reaction that requires intense immune suppression before eventual resolution.
Bonney
Denise K
DK
O'Meara
Anne
A
Shabani
Abdu
A
Imrie
Jackie
J
Bigger
Brian W
BW
Jones
Simon
S
Wraith
James E
JE
Wynn
Robert F
RF
D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D001921:Brain / Q000473:pathology; D002352:Carrier Proteins / Q000235:genetics*; D002657:Child Development; D004334:Drug Administration Schedule; D018698:Glutamic Acid; D006023:Glycoproteins / Q000172:deficiency / Q000235:genetics*; D006086:Graft vs Host Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy; D006720:Homozygote; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000276:immunology; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007223:Infant; D008264:Macrophages / Q000187:drug effects / Q000276:immunology / Q000637:transplantation*; D008279:Magnetic Resonance Imaging; D008297:Male; D009048:Motor Skills; D009154:Mutation; D052556:Niemann-Pick Disease, Type C / Q000235:genetics / Q000601:surgery*; D010641:Phenotype; D011014:Pneumonia / Q000276:immunology; D012141:Respiratory Tract Infections / Q000276:immunology* / Q000628:therapy; D012720:Severity of Illness Index; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D033921:Vesicular Transport Proteins
D002352:Carrier Proteins; D006023:Glycoproteins; D007166:Immunosuppressive Agents; C104585:NPC2 protein, human; D033921:Vesicular Transport Proteins; D018698:Glutamic Acid
Clin Genet. 2003 Oct;64(4):269-81
12974729
Lancet. 2009 May 2;373(9674):1550-61
19282026
Clin Genet. 2007 Apr;71(4):320-30
17470133
Am J Hum Genet. 1983 Nov;35(6):1081-5
6417999
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14944-9
9843995
Blood. 2008 Dec 1;112(12):4371-83
19029455
Am J Hum Genet. 2001 Nov;69(5):1013-21
11567215
Virchows Arch. 2001 Aug;439(2):206-11
11561763